Cambridge Healthtech Institute’s 2nd Annual

Antivirals: Targeting HBV and Beyond  
( 抗病毒剂:B型肝炎病毒 (HBV) 及各种病毒的标靶化 )

September 25, 2018

Antiviral drug development is shifting its focus to hepatitis B virus (HBV) after the encouraging success of developing direct-acting antivirals against the hepatitis C virus. Both viruses cause liver disease and represent major global health problems that can lead to death from liver failure. Much of the research focuses on broadly applicable antiviral approaches that modulate the host’s immune system or other infection response processes. Host immunomodulatory strategies are also being applied for treating emerging viral diseases. Progress has also been made in several HBV-specific approaches such as RNAi to silence HBV gene production, or inhibit the virus’ capsid assembly, which are in early-stage clinical trials or may be soon. Join us at CHI's Antivirals: Targeting HBV and Beyond symposium to stay abreast of new drug  development in the HBV and broader infectious disease field and to share insights and strategies with fellow researchers.

Who should attend: Virologists, Discovery Biologists, Infectious Disease Researchers, Discovery Chemists, Pharmacologists from academics or industry (biotech and pharma) in departments or areas of focus such as infectious diseases, antivirals, liver disease, and immunology

Coverage will include, but is not limited to:                                        

  • Clinical updates for HBV drug development
  • New HBV drug targets
  • Modulating host innate immune system (e.g. toll-like receptor agonists, checkpoint inhbitors)
  • Targeting host lipid metabolism for broad-spectrum antivirals
  • Targeted degradation approaches for infectious diseases
  • Antivirals for emerging diseases: Zika, Dengue


* 活动内容有可能不事先告知作更动及调整。

Choose your language